Avenue Therapeutics announces publication on teal-world data on NMU of tramadol

Avenue Therapeutics announced that a publication titled "Real-World Data on Nonmedical Use of Tramadol from Patients Evaluated for Substance Abuse Treatment in the NAVIPPRO Addiction Severity Index-Multimedia Version Network" has been published in Drug Safety, a peer-reviewed international journal covering pharmacoepidemiology and pharmacovigilance. The objective of the study was to evaluate nonmedical use and diversion of tramadol and comparator opioids using real-world data from the Addiction Severity Index-Multimedia Version. A cross-sectional study design was used to evaluate past 30-day tramadol and comparator opioid NMU among adults assessed for substance abuse treatment using the ASI-MV from 2010-2018. The paper concluded that tramadol had a significantly lower rate of NMU than comparator opioids and was less likely to be diverted or used via higher-risk non-oral routes, and that these findings support previous evaluations by WHO and the United States Drug Enforcement Agency that concluded that tramadol has a low potential for abuse.